الفهرس 
HEPATITIS C VIRUSOnly 14 pages are availabe for public view
 |  | from | 185 |  |  |
| | | from | 185 | | |
Abstract
Hepatitis C virus (HCV) infection is one of the leading causes of chronic hepatitis worldwide and is also a major risk factor for the disease progression to advanced entities such as liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC). With the emergence of directly acting antivirals (DAAs), a new hope was found for HCV cure and eradication.
The aim of our study was to monitor the safety of interferon-free (IFN-free), sofosbuvir-based (SOF-based) DAAs, with special emphasis on hepatic decompensation, HCC and renal impairment as adverse effects of the therapy and also to assess the efficacy of included agents.
To fulfill this aim, the current study was done over 140 chronic hepatitis C (CHC) patients, in the period from October 2017 till December 2019. Included patients met the National Committee for the Control of Viral Hepatitis (NCCVH) criteria of HCV treatment. They were subjected to thorough history taking and clinical examination, full laboratory assessment, evaluation of FIB-4, and pelvi-abdominal ultrasound. Dynamic imaging such as triphasic computerized tomography (CT) or dynamic magnetic resonance imaging (MRI) liver could have been requested if patients were suspected to have any hepatic focal lesion or elevated alfa feto protein (AFP). Also, HCV RNA PCR was requested to assess the efficacy of treatment. Included patients were either starting treatment, during treatment or at their follow-up visits for 1 year after EOT.
Included patients were divided according to the regimen taken into group I who received sofosbuvir/daclatasvir (SOF/DAC) for 12 weeks, group II who received sofosbuvir/daclatasvir/ribavirin (SOF/DAC/RBV) for 12 weeks, group III who received sofosbuvir/simeprevir (SOF/SIM) for 12 weeks, group IV for SOF/RBV for 24 weeks and group V for SOF/DAC/RBV for 24 weeks.